Ong Jeremy Sl, Whitewood Felicity, Taylor Donna B, Dissanayake Deepthi
Medical Imaging, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.
Department of Nuclear Medicine, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
BMJ Case Rep. 2019 Oct 5;12(10):e230043. doi: 10.1136/bcr-2019-230043.
Molecular breast imaging (MBI) is a relatively new technique with high sensitivity for breast cancer detection. However, because it only provides limited anatomical information, cross-correlation of MBI findings with conventional breast imaging modalities such as full field digital mammography can be challenging. We report a case of a positive MBI study in a supplemental screening setting, where cross-correlation of MBI, ultrasound, mammogram and biopsy findings was difficult. Contrast-enhanced spectral mammography (CESM) demonstrated a hypervascular lesion at the biopsy clip, helping to prove imaging/histopathological concordance. This case highlights the challenges of incorporating MBI into conventional imaging workup, as well as the use of CESM in problem solving.
分子乳腺成像（MBI）是一种相对较新的技术，对乳腺癌检测具有高灵敏度。然而，由于它仅提供有限的解剖学信息，将MBI检查结果与传统乳腺成像模式（如全场数字化乳腺摄影）进行相互关联可能具有挑战性。我们报告了一例在补充筛查环境中MBI检查呈阳性的病例，其中MBI、超声、乳腺X线摄影和活检结果的相互关联存在困难。对比增强光谱乳腺摄影（CESM）显示活检夹处有一个血管丰富的病变，有助于证实影像/组织病理学一致性。该病例突出了将MBI纳入传统成像检查流程的挑战，以及CESM在解决问题中的应用。
